Kornimate/medical-research-clean huggingface dataset:
comparison of two cementing techniques of the femoral component in a hip prosthesis

Conditions: Osteoarthritis, Hip

Summary: the primary aim of the study is to compare migration of the cemented corail stem representing polished surfaced versions of the femoral stem. two different methods will be used for reaming the femoral canal and cementing of the stem. radiostereometric analysis (rsa) will be used in migration measurements. furthermore pain, postoperative outcome and patient satisfaction will be assessed.


Eligibility criteria:
inclusion criteria: * patients requiring cemented primary total hip replacement. * patients with a diagnosis of osteoarthritis, avascular necrosis or post-traumatic arthritis * patients who understand the conditions of the study and are willing and able to comply with the post-operative scheduled clinical and radiographic evaluations and the prescribed rehabilitation * patient who signed the ethics committee approved specific informed consent form prior to surgery exclusion criteria: * patients who require revision of a previously implanted total hip replacement (thr) * patients who will receive a thr without cement * patients who have had a prior procedure of osteotomy on the femur * obese patients where obesity is severe enough to affect subject's ability to perform activities of daily living (body mass index, kg/m2: bmi \>35) * patients with active or suspected infection * patients with malignancy

Keywords: hip prosthesis surgery cements radiostereometric analysis
pg2 injection 500 mg in acute stroke study (pass)

Conditions: Acute Stroke

Summary: the primary objective of this study is to evaluate the efficacy of pg2 injection 500 mg versus placebo, administered intravenously within 3-6 hrs of stroke onset to patients with an acute ischemic stroke, as determined by modified rankin scale (mrs) score at day 90. the secondary objectives are as follows: * to evaluate the efficacy of pg2 injection 500 mg versus placebo as determined by barthel index (bi) score at day 90. * to evaluate the efficacy of pg2 injection 500 mg in reducing the risk of recurrent stroke, cardiovascular events and death of all causes. * to evaluate the safety of pg2 injection 500 mg treatment

randomized, double-blind, placebo-controlled multi-center study of intravenous (iv) pg2 injection 500 mg starting within 3-6 hrs of the onset of acute ischemic stroke

Eligibility criteria:
inclusion criteria: 1. patients presenting with acute ischaemic stroke 2. patient, or a family member with legally authorized responsibility, has given informed consent 3. age ≥20 years 4. infusion of study medication can be started within 3-6 hrs of stroke onset. 5. nihss score of ≥ 7 - 24 exclusion criteria: 1. intracranial haemorrhage (ich) identified by ct or mri 2. rapidly improving symptoms, particularly if in the judgment of the managing clinician that the improvement is likely to result in the patient having an nihss score of \< 6 at randomization 3. pre-stroke mrs score of ≥ 2 (indicating previous disability) 4. known allergy to astragalus membranaceus or its mayor derivatives (polysaccharides) 5. patients who are eligible for tpa treatment and has been treated with tpa. 6. participation in any investigational study in the previous 30 days 7. any terminal illness such that patient would not be expected to survive more than 1 year 8. any condition that could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study (this applies to patients with severe microangiopathy such as haemolytic uremic syndrome or thrombotic thrombocytopenic purpura). the judgment is left to the discretion of the investigator 9. pregnant women (clinically evident) 10. previous stroke within last three months 11. past history or clinical presentation of ich, arterio-venous (av) malformation, aneurysm, or cerebral neoplasm. 12. current use of oral anticoagulants with prolonged prothrombin time (inr \> 1.6) 13. use of heparin, except for low dose subcutaneous heparin, in the previous 48 hrs and a prolonged activated partial thromboplastin time exceeding the upper limit of the local laboratory normal range 14. clinically significant hypoglycaemia (blood sugar \< 50mg/dl) 15. uncontrolled hypertension defined by a blood pressure \> 185 mmhg systolic or \>110 mmhg diastolic on at least 2 separate occasions at least 10 minutes apart, or requiring aggressive treatment to reduce the blood pressure to within these limits. the definition of "aggressive treatment" is left to the discretion of the responsible investigator 16. major surgery within the preceding 14 days which poses risk in the opinion of the investigator
the effect of green tea extract on type 2 diabetes with hyperlipidemia

Conditions: Type 2 Diabetes; Hyperlipidemia

Summary: the aim of the study is to examine whether the extract of green tea is effective on type 2 diabetes and hyperlipidemia.

percent change homa insulin resistance, cholesterol and triglycerol.

Eligibility criteria:
inclusion criteria: * age 20--69 years old * type 2 diabetes for \> one year * tg \>= 150 mg/dl or ldl \>= 100 mg/dl exclusion criteria: * gpt \> 80 mg/dl * creatinine \> 1.8 mg/dl * pregnancy * ami * stroke * operational or any not suitable patients diagnosis physician in charge

Keywords: green tea egcg type 2 diabetes hyperlipidemia
dynamic locking screws 5.0 vs. standard locking screws in fracture of distal femur treated with locked plate fixation

Conditions: Distal Femur Fractures

Summary: the purpose of this study is to evaluate the performance of dynamic locking screws (dls) used to stabilize the shaft component of distal femur fractures in comparison to standard locking screws (sls). the hypothesis is that dls will lead to better functional outcomes (womac score) due to increased and more symmetrical callus formation and fewer non-unions.


Eligibility criteria:
inclusion criteria: * 21 years and older * closed or open distal femur fracture (ao 33 a1-3, 33 c1-3) including distal femur fractures above a total knee arthroplasty * ability to walk independently prior to injury * eligible for treatment with orif of the distal femur with a large fragment locking plate (liss, lcp) * willing and able to comply with post-operative protocol and return for follow-up. * ability to understand the content of the patient information / informed consent form and participate in the clinical investigation * signed informed consent exclusion criteria: * additional ipsi- or contralateral lower extremity fracture * any kind of implant at the ipsilateral proximal femur * pre-existing malunion or nonunion of the ipsilateral lower extremity * segmental bone defect requiring bone grafting * more than 4 weeks between injury and surgery * pathologic fracture due to a disease other than osteoporosis (eg, tumor, metastasis) * polytrauma * active malignancy * any not medically managed severe systemic disease * recent history of substance abuse (ie, recreational drugs, alcohol) that would preclude reliable assessment * pregnancy or women planning to conceive within the study period * prisoner * participation in any other medical device or medicinal product study within the previous month that could influence the results of the present study

Keywords: femoral fracture periprosthetic fracture fracture fixation, internal distal femur fractures dynamic locking screw womac
interest of the heart score for the management of patients with chest pain in emergency department

Conditions: Acute Coronary Syndrome

Summary: chest pain is a frequent reason of consultation in emergency department. emergency physician have to identify patients at high risk of acute coronary syndrome from those presenting a lower risk.

the aim of the study is to study the interest of the heart score for the management of patients with chest pain in emergency department

Eligibility criteria:
inclusion criteria: men and women aged more than 18 chest pain consulting in emergency department agreeing to participate to the study exclusion criteria: aged less than 18 not agreeing to participate to the study

Keywords: acute coronary syndrome chest pain emergency department heart score
the use of breath volatile organic compounds in early detection of acute pulmonary exacerbations in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: this is a single-centre, prospective observational cohort study assessing the potential utility of the owlstone medical "breath biopsy" in early diagnosis of pulmonary infections in patients with cystic fibrosis (cf). in cystic fibrosis pulmonary infections occur frequently and are associated with decline in lung function and disease progression, therefore a cornerstone of cf management is early identification and treatment of infections. "breath biopsy" is a non-invasive novel technology that has been trialled extensively in diagnosis of a variety of medical conditions with promising results. the technology is based the identification of a unique profile of organic compounds in exhaled breath of patients with a certain medical condition. making the diagnosis of pulmonary infections in patients with cf is clinically challenging and at present relies on imprecise diagnostic tests, and generally requires attendance of patients to hospital or clinic for assessment. ultimately, this research aims to assess the feasibility of incorporating "breath biopsy" into this diagnostic pathway with the advantages of both improving diagnostic certainty and potentially allowing in-home diagnosis of infections related to cf. furthermore, identification of organic compounds implicated in cf infections will improve the understanding of why these infections occur, which to date remains an area that is poorly understood. five patients with cf-related pulmonary infections admitted to the inpatient cf unit at the royal papworth hospital will be enrolled, and use "breath biopsy" devices provided by owlstone medical to collect breath samples from these patients in order to determine whether a unique organic compound profile can be identified in cf exacerbations.


Eligibility criteria:
inclusion criteria: 1. diagnosis of cystic fibrosis based on genetic testing and/or sweat chloride levels 2. f508del homozygous or heterozygous (f508del with another severe cftr mutation) 3. age over 18 years 4. able to provide written informed consent 5. current exacerbation requiring inpatient or outpatient treatment at royal papworth hospital. 6. chronic infection with pseudomonas aeruginosa, as defined as \>50% of sputum culture or cough swabs being positive in the preceding 12 months 7. baseline fev1 30%-with no predicted upper limit exclusion criteria: 1. patients unable to provide written informed consent 2. patients whose clinical status precludes use of the reciva (mask) breath sampler due to oxygen dependency or tachypnoea 3. patients who require admission to intensive care 4. lung transplant recipients
inhaled apocynin decreases reactive oxygen species concentrations in exhaled breath condensate in mild asthmatics

Conditions: Bronchial Asthma

Summary: the aim of the study is to investigate the effect of inhaled apocynin on ros (reactive oxygen species) and nos (reactive nitrogen species) synthesis in 10 nonsmoking mild asthmatics. effects of nebulized apocynin (0.5 mg/ml, 6 ml) are assessed in exhaled breath condensate (ebc) after 30, 60 and 120 minutes.

the study had a double-blind, placebo-controlled, cross-over design, consisted of 2 visits, separated 30 ± 10 days. if during the first visit the drug was used, in the second visit - placebo or vice versa. before and after procedure, safety measures (arterial blood pressure, heart rate value, and cough scale) were performed. the effect of a possible inhibitor of ros formation was performed using corticosteroid-naive asthmatic subjects, which are more prone to oxidative stress than healthy non-smoking subjects. the study protocol was approved by the ethics committee of medical university of lodz (no. rnn/12/08/ke) and written consent was obtained from every subject prior to the study. ebc was collected using a modification of the method described previously by doniec et al.2005. the subjects breathed spontaneously through a mouthpiece for 20 min. each subject wore a nose clip during this procedure. approximately 2 ml of condensate was collected and immediately stored at -80°c until the procedure of h2o2, no2- and no3- measurement. 6 ml of apocynin of total dose 3 mg (0.5 mg/ml) has been nebulized through the mouthpiece with using of a nose clip. the h2o2 concentration in ebc was measured according to the method applied previously by nowak et al.2001. determination of no2- and no3- with griess solution was performed by micromethod, carried out in 96-well plates, according to griess' method, modified the method described by dziedzic et al.2003.

Eligibility criteria:
inclusion criteria: * patients suffering from bronchial asthma (mild) * patients free of any medication at least 7 days before research * patients had not suffered from any infectious diseases including upper respiratory tract infections for at least 3 months prior to the study exclusion criteria: * patients suffering from moderate or severe asthma * patients taking medication 7 or less days before the study * infectious diseases that had occurred 3 months or less before the study

Keywords: apocynin asthma
limbal stem cell derived exosome (lsc-exo) eye drop for treatment of dry eye

Conditions: Dry Eye Syndromes

Summary: the purpose of this study is to determine the safety and efficacy of limbal stem cells derived exosomes (lsc-exo) in alleviation of dry eye symptoms

dry eye is among the most prevalent chronic conditions in ophthalmology, significantly impacting quality of life and presenting a public health challenge that cannot be overlooked. current treatment options primarily consist of artificial tear replacement, anti-inflammatory therapies, and local immunosuppressive treatments, which mainly focus on alleviating discomfort and other symptoms associated with the ocular surface. however, with the rapid advancements in regenerative medicine, ophthalmologists are exploring innovative approaches to treat dry eye. chronic dry eye can result in corneal damage and potential vision loss. recent studies suggest that therapeutic exosomes delivered as eye drops can enhance the immune microenvironment of the cornea and alter the ocular surface\&#39;s microenvironment for better outcomes. exosomes are membrane vesicles secreted by parental cells, which can mediate the transfer of rna, protein, dna and other functional molecules of the parent cell between other cells and regulate the function of target cells. the therapeutic potential of limbal stem cell exosomes has been studied by our department. we found that lsc-exo can alleviate the symptoms of dry eye in the animal study. at present, we plan to clarify its efficacy in a clinical research. the main objective of this study is to evaluate the alleviation of dry eye symptoms in patients which are resist to conventional treatment by tear drops. the assessment will be done after lsc-exo treatment by measuring ocular surface index score (osdi), and the second objective include the measurement of inflammatory and pro-inflammatory cytokines in tear of patients, tear secretion amount, tear break time, the areas stained by fluorescent, ocular redness, tear meniscus and best corrected visual acuity. approximately 30 patients will be recruited. the treatment group will receive artificial tears for 2 weeks to normalize the baseline, followed by intervention of lsc-exo 10ug/drop, four times a day for 30 days. the follow-up visit will be 12-weeks and the progression of dry eye will be measured.

Eligibility criteria:
inclusion criteria: * patients with complaints of burning or itching or feeling of a foreign body in the eye * moderate and severe dry eye severity * age between 18-70 years exclusion criteria: * previous history of eye surgery * any disease that suppresses the immune system * pregnancy and breastfeeding * eyelid abnormalities * use of eye drops in the past year except artificial tears and lubricating ointments * use of systemic drugs that affect the tear film in last three months * use of contact lenses in the last three months

Keywords: dry eye disease sjogren's syndrome chronic dry eye
a 10-week study for efficacy and safety study of gabitril in the treatment of adults with generalized anxiety disorder

Conditions: Generalized Anxiety Disorder

Summary: the purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (gad).


Eligibility criteria:
inclusion criteria: • subjects 18 to 64 years of age (inclusive) will be eligible to participate if they satisfy the dsm-iv-tr criteria for gad, as well as meeting the required screening and baseline visit scores for a series of psychiatric evaluations (i.e., ham-a, hads, madrs and cgi-s). exclusion criteria: * have been previously unresponsive to two or more adequate courses of pharmacological treatment for gad * have been diagnosed with any other psychiatric axis i disorder (except gad) as a principal diagnosis within the past six months * have been diagnosed with any eating disorder within the past six months * have any history of ocd, psychotic disorder, bipolar disorder or antisocial personality disorder * have any history of alcohol or substance abuse within 3 months of screening * have any history of seizures, including febrile seizures * have any history of head trauma associated with loss of consciousness within the past 15 years
efficacy and safety of lactobacillus acidophilus/rhamnosus combination for the prevention of antibiotic-associated diarrhea in the elderly

Conditions: Diarrhea; Clostridium Difficile

Summary: the purpose of this study is to determine whether lactobacillus acidophilus/rhamnosus complex is effective in the prevention of antibiotic-associated diarrhea (aad) in the elderly.

antibiotic-associated diarrhea (aad) is a common adverse drug reaction, occurring in 5-35% of patients, and is of significant consequence to hospitalized patients. patients who develop aad are more likely to experience a longer hospital stay, incur higher medical costs, and develop other co-morbidities. clostridium difficile infection (cdi) accounts for approximately 15-25% of aad cases and is a significant cause of morbidity and mortality in hospitalized geriatric patients. a preventative measure that has been suggested for aad and cdi is the use of probiotics. although probiotics have been used for a wide range of indications, including the prevention and treatment of aad and cdi, there is lack of data regarding efficacy of these products. hospitalized elderly patients are at significant risk of developing aad and cdi and prevention of aad and cdi in this population may contribute to a reduction in morbidity, length of hospital stay, medical costs, and potentially mortality.

Eligibility criteria:
inclusion criteria: * inpatients over the age of 60 on 4a/b unit at victoria general hospital, victoria bc, and * anticipated to receive antibiotics (intravenous or oral) for greater than 72 hours for any indication, and * are determined to be competent by the prescriber. exclusion criteria: * patients who have been on antibiotics during the past 2 weeks * patients who have active diarrhea at enrollment * patients who have been diagnosed with cdi within the previous 3 months * patients who are lactose intolerant * patients who have an underlying chronic gi tract disease (inflammatory bowel disease, irritable bowel syndrome) * patients who have an ileostomy or colostomy * patients who regularly take probiotics * patients who are severely immunocompromised (hiv positive, transplant patient, on antirejection medications, on a steroid for \>30 days, or chemotherapy or radiotherapy within the last year) * patients who have a life-threatening illness * patients who cannot take medications by mouth or are tube fed * patients who have been on the new antibiotic for more than 72 hours * patients who are anticipated to receive the new antibiotic for a duration of less than 72 hours * patients who do no give informed consent.

Keywords: antibiotics diarrhea clostridium difficile probiotics prevention & control
v shaped plate vs champy technique in mandibular angle fractures

Conditions: Fractures, Bone

Summary: assessing fixation of mandibular angle fracture using two different mini plates, the standard champy technique and the new v shaped plate with comparing occlusion and condylar position between the two plates.

the mandible is one of the most frequent bones of the face that is susceptible to fractures because its prominent position, as it comes in the second place after nasal fractures . mostly, such fractures are a result of trauma caused by vehicle accidents, physical altercations, industrial accidents, falls, and contact sports, males usually suffer from mandibular fractures more than females. the angle of the mandible is the most frequent area of the mandible to be fractured after the body, the reasons behind that is the presence of a third molar especially if it was impacted one which weakens the region even more, another reason is the existence of a very thin cross sectional area compared to the anterior parts of the mandible. most common causes of mandibular angle fractures are motor vehicle collisions and assaults or altercations. therefore, the aim of this study is to evaluate a novel method which is using a (v) shaped plate in fixation of mandibular angle fracture, the new (v) shaped plate have provided easy reduction and stabilized fixation along both sides of the fracture, as it has two arms that can be easily adjusted over the angle of the mandible covering both lines of osteosynthesis along the superior border and lateral surface of the external oblique ridge using a single plate. although champy technique has been proven to be successful way for treating angle fractures with low complication rates it covers only one line of osteosynthesis which is the superior border of external oblique ridge unlike the (v) shaped plate.

Eligibility criteria:
inclusion criteria: 1. patients with unilateral angle fracture. 2. patients free from any systemic diseases that affect bone healing. 3. no sex predilection. 4. age 18-50 exclusion criteria: 1. comminuted angle fractures. 2. infected angle fracture. 3. bilateral angle fracture. 4. patients with any systemic diseases that affect bone healing.

Keywords: champy angle fracture